Ratings by Stifel (Derek Archila)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
7/13/2021 PhaseBio Pharmaceuticals Inc. PHAS Maintain Buy
(N/A)
 
 
  Details
6/14/2021 Equillium EQ Maintain Buy
(N/A)
 
 
  Details
5/24/2021 NGM Biopharmaceuticals NGM Maintain Buy
(N/A)
 
 
  Details
5/17/2021 Apellis Pharmaceuticals APLS Maintain Buy
(N/A)
 
 
  Details
5/14/2021 Equillium EQ Maintain Buy
(N/A)
 
 
  Details
4/29/2021 Apellis Pharmaceuticals APLS Maintain Buy
(N/A)
 
 
  Details
4/6/2021 Prometheus Biosciences Inc RXDX New Coverage Buy
(N/A)
18.18
(26.15)
43.84% Details
3/11/2021 Lumos Pharma LUMO New Coverage Buy
(N/A)
13.25
(10.01)
-24.45% Details
3/11/2021 Ascendis Pharma ASND New Coverage Buy
(N/A)
143.99
(161.51)
12.17% Details
2/2/2021 Immunovant IMVT Maintain Buy
(N/A)
 
 
  Details
2/2/2021 Immunovant IMVT Maintain Buy
(N/A)
 
 
  Details
10/8/2020 Immunovant IMVT New Coverage Buy
(N/A)
36.75
(15.16)
-58.75% Details
9/1/2020 Apellis Pharmaceuticals APLS New Coverage Buy
(N/A)
26.87
(34.21)
27.32% Details
9/1/2020 Alexion Pharmaceuticals ALXN New Coverage Hold
(N/A)
106.99
(182.01)
70.12% Details
8/11/2020 Equillium EQ Maintain Buy
(N/A)
 
 
  Details
8/4/2020 Inventiva SA IVA New Coverage Buy
(N/A)
10.19
(13.90)
36.41% Details
7/13/2020 Equillium EQ Maintain Buy
(N/A)
 
 
  Details
7/10/2020 Galapagos NV GLPG Downgrade Hold
(Buy)
201.07
(55.64)
-72.33% Details
7/10/2020 PhaseBio Pharmaceuticals Inc. PHAS New Coverage Buy
(N/A)
4.65
(2.89)
-37.85% Details
7/10/2020 Equillium EQ New Coverage Buy
(N/A)
2.80
(6.38)
127.86% Details
6/17/2020 Amarin Corporation AMRN Maintain Hold
(N/A)
 
 
  Details
5/12/2020 CymaBay Therapeutic CBAY Upgrade Buy
(Hold)
1.84
(3.82)
107.61% Details
3/31/2020 Amarin Corporation AMRN Maintain Hold
(N/A)
 
 
  Details
3/19/2020 NGM Biopharmaceuticals NGM Maintain Buy
(N/A)
 
 
  Details
3/11/2020 Principia Biopharma PRNB Maintain Buy
(N/A)
 
 
  Details
2/26/2020 Vanda Pharmaceuticals VNDA Maintain Hold
(N/A)
 
 
  Details
2/25/2020 NGM Biopharmaceuticals NGM Maintain Buy
(N/A)
 
 
  Details
12/23/2019 Principia Biopharma PRNB Maintain Buy
(N/A)
 
 
  Details
12/16/2019 Amarin Corporation AMRN Downgrade Hold
(Buy)
24.12
(5.15)
-78.65% Details
12/4/2019 NGM Biopharmaceuticals NGM Maintain Buy
(N/A)
 
 
  Details
11/25/2019 CymaBay Therapeutic CBAY Downgrade Hold
(Buy)
5.55
(1.84)
-66.85% Details
11/12/2019 Amarin Corporation AMRN Maintain Buy
(N/A)
 
 
  Details
10/2/2019 Principia Biopharma PRNB Maintain Buy
(N/A)
 
 
  Details
7/25/2019 Vanda Pharmaceuticals VNDA Downgrade Hold
(Buy)
12.69
(16.95)
33.57% Details
6/25/2019 Madrigal Pharmaceuticals MDGL New Coverage Hold
(N/A)
104.86
(81.74)
-22.05% Details
6/25/2019 Intercept Pharmaceuticals ICPT Upgrade Hold
(N/A)
81.39
(15.93)
-80.43% Details
6/25/2019 CymaBay Therapeutic CBAY New Coverage Buy
(N/A)
7.07
(5.55)
-21.5% Details
6/25/2019 Genfit GNFT New Coverage Hold
(N/A)
20.20
(3.86)
-80.89% Details
6/25/2019 Viking Therapeutic VKTX New Coverage Buy
(N/A)
8.01
(6.69)
-16.48% Details
6/24/2019 NGM Biopharmaceuticals NGM New Coverage Buy
(N/A)
13.80
(23.03)
66.88% Details
5/29/2019 Amarin Corporation AMRN Maintain Buy
(Buy)
 
 
  Details
5/2/2019 Vanda Pharmaceuticals VNDA Maintain Buy
(N/A)
 
 
  Details
4/17/2019 Principia Biopharma PRNB New Coverage Buy
(N/A)
27.81
(100.05)
259.76% Details
3/27/2019 Amarin Corporation AMRN Maintain Buy
(N/A)
 
 
  Details
3/22/2019 Amarin Corporation AMRN New Coverage Buy
(N/A)
19.01
(24.12)
26.88% Details
12/10/2018 Vanda Pharmaceuticals VNDA Maintain Buy
(N/A)
 
 
  Details
12/3/2018 Vanda Pharmaceuticals VNDA Maintain Buy
(N/A)
 
 
  Details